

H1 FY19 HEADLINES

Exceptional performance in a challenging environment

REVENUES \$377.0M UP 14% ON FY18

- Strong performance in connectivity and devices
- Innovation in accessory brand Sprout™
- Non-invasive medical aesthetics (NIMA) starting to scale
- SQDAthleticaTM gaining momentum

EBITDA \$25.0M UP 25% ON H1 FY18 AHEAD OF GUIDANCE

- Retail ICT and Sprout[™] significant growth
- Labour productivity gains
- Small but positive NIMA contribution
- Interim dividend 5.2cps (\$8.4m, up 16%)

STRONG AND FLEXIBLE **BALANCE SHEET**

- Strong cash generation
- Disciplined investment
- Net cash \$17.2m

Results demonstrate significant progress in executing our strategy



INCOME STATEMENT

(\$m unless otherwise stated)		H1 FY18	Change
Revenue	377.0	329.6	14%
Gross Profit	115.6	103.3	12%
Gross Profit %	30.7%	31.3%	
EBITDA	25.0	20.0	25%
EBIT	19.9	15.7	27%
NPAT	14.1	11.2	26%
Interim dividend	8.4m	7.3m	16%
Interim dividend	5.2cps	4.7cps	11%
Earnings per share	8.8cps	7.3cps	20%



Information and Communication Technology (ICT) up strongly

- Robust device and connectivity volumes
- Innovative solutions and distribution gains from Sprout[™] accessories
- Growth in revenues from business customers

NIMA growing

 Clinic portfolio performing well; channel growing through acquisitions and greenfields

SQDAthletica™ building

Brand awareness and revenues up

Gross profit up 12% to \$115.6m

- Revenue growth
- Slight reduction in rate, reflecting mix movements

EBITDA up 25%

- Strong EBITDA growth improvement in all channels
- EBIT up 27%

Strong dividend growth

- Dividend \$8.4m, up 16%
- Interim dividend 5.2cps



BALANCE SHEET

(\$m unless otherwise stated)		31 Dec 17
Cash	27.1	22.5
Current assets (exc. cash)	60.8	47.9
Non-current assets	126.4	115.6
Total Assets	214.3	186.0
Current liabilities	(97.0)	(88.6)
Non-current liabilities	(11.0)	(10.1)
Total Liabilities	(108.1)	(98.7)
Net Assets	106.2	87.3
Cash	27.1	22.5
Debt	(9.8)	(10.9)
Net Cash	17.2	11.6



- Strong cash conversion
- Lower investing cash flows compared to prior year

Tight management of working capital

- Inventory at two weeks, but up due to increased products sales and NIMA expansion (+ \$7.3m)
- Receivables up on timing of receipts (+ \$5.8m)

Non-current assets up

• Intangibles and goodwill up on acquisitions (+ \$8.3m) in last 12 months

Current liabilities up

- Payables up (+ \$8.3m) due to higher device purchases
- Offset by lower current debt (- \$1.9m)

Non-current liabilities marginally up

• Higher levels of non-current debt (+ \$0.9m)

Healthy debt position – no net debt

- \$9.8m gross debt at period end
- Net cash \$17.2m



CASH FLOW

(\$m unless otherwise stated)		H1 FY18
Operating cash flows	13.4	18.0
Investing cash flows	(6.7)	(13.2)
Financing cash flows	(11.2)	(12.0)
Net Cash Movement	(4.5)	(7.2)
Opening cash balance	31.6	29.7
Closing cash balance	27.1	22.5

Operating cash flows

• Strong cash conversion but lower than prior year due to timing of receipts


Investing cash flows

- Capex directed towards acquisitions (\$1.8m), fitouts (\$2.9m), and IT (\$1.2m), offset by proceeds from sale of store (+ \$0.6m)
- Lower spend on acquisitions compared to prior year

Financing cash flows

- Repayment of borrowings (\$5.3m)
- No drawdown of debt
- Dividends net of DRP proceeds (\$5.9m)






Information & Communication Technology


- Retail performing strongly, delivering record revenues through:
 - Benefits of physical portfolio optimisation
 - Continued focus on consulting and personalised service
 - Small business customers (1-10 seats) now serviced through retail
 - Strong contribution from devices, connectivity and accessory categories in particular Vita's proprietary accessory brand Sprout™, which continued to deliver innovation across a range of products
- Business ICT transforming to service higher value customers with more holistic products and services – serviced through expanded territories
- Strategic partnership with Telstra solid tenure extended to 2024





Non-Invasive Medical Aesthetics

- Foundations in place
 - ▶ Six Clear Complexions™ clinics embedded; earnings ahead of plan
 - Operating structure implemented
 - Medical Board established led by Medical Director (acting)
 - Artisan Aesthetic Clinics brand rolling out
 - National brand ambassador appointed Susie O'Neill
 - ▶ 10 clinics operating at 31 December, including two Artisan greenfields
- Artisan Aesthetic Clinics ready to scale
 - Healthy pipeline of acquisitions and greenfield opportunities
 - Refining operating practices to drive productivity
- Added significant capability through the acquisitions of
 - ▶ Face AcademyTM: a medical training organisation
 - Cosmedcloud: an industry-leading cloud-based software product



Our focus in the second half

Information and Communication Technology

- Continue to optimise physical portfolio, including new store formats
- Further embed delivery of personalised customer experience through consulting
- Continue to maximise Sprout[™] through premium product innovation
- Grow small business in retail
- Continue transition of Business ICT to new model

ICT remains the profit engine of the group

Non-Invasive Medical Aesthetics

- Drive performance and profitability through operating disciplines
- Add scale through acquisitions and greenfields (target 15-18 by June 30)
- Rebrand acquisition portfolio to Artisan Aesthetic Clinics, with bespoke fitout for each clinic
- Drive best practice in safety and medical standards through Medical Board
- Evaluate opportunity for verticals to complement our clinic and training offering

Significant mid-long term value potential

$SQDAthletica^{TM}$

- Expand range
- Capitalise on momentum in all channels

Niche mid-term value opportunity



H1 FY19 SUMMARY

H1 PERFORMANCE AHEAD OF MARKET GUIDANCE

STRONG EARNINGS AND DIVIDEND GROWTH

FOCUS ON EXECUTING STRATEGY **CONTINUED GROWTH AND PROFITABILITY** IN ICT

ICT REMAINS PROFIT ENGINE OF THE GROUP SIGNIFICANT PROGRESS **SCALING NIMA**

HIGH MID-LONG TERM **GROWTH POTENTIAL**

Strong and flexible balance sheet to allow investment in growth initiatives





DISCLAIMER

The material in this presentation is a summary of Vita Group Limited's (Vita) activities and results, and is current at the date of preparation, 22 February 2019. Further details are provided in the Company's full year accounts and results announcement released on 22 February 2019.

No representation, express or implied, is made as to the fairness, accuracy, completeness or correctness of information contained in this presentation, including the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in the presentation ("forward-looking statements"). Such forward-looking statements are by their nature subject to significant uncertainties and contingencies and are based on a number of estimates and assumptions that are subject to change (and in many cases are outside the control of Vita and its Directors) which may cause the actual results or performance of Vita to be materially different from any future results or performance expressed or implied by such forward-looking statements. Undue reliance should not be placed on forward-looking statements and except as required by law or regulation, Vita assumes no obligation to update these forward-looking statements. To the maximum extent permitted by law, Vita and its related corporations, Directors, officers, employees and agents disclaim any obligations or undertaking to release any updates or revisions to the information in this presentation to reflect any change in expectation or assumptions and disclaim all responsibility and liability for these forward-looking statements (including without limitation, liability for fault or negligence).

This presentation provides information in summary form only and is not intended to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor.

Due care and consideration should be undertaken when considering and analysing Vita's financial performance. All references to dollars are to Australian Dollars unless otherwise stated.

To the maximum extent permitted by law, neither Vita nor its related corporations, Directors, officers, employees or agents, nor any other person, accepts any liability, including, without limitation, any liability arising from fault or negligence, for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it.

Certain financial data included in this presentation may be "non-IFRS financial information" under Regulatory Guide 230 Disclosing non-IFRS financial information published by ASIC. [The non-IFRS financial information in this presentation may include underlying profit after tax]. Vita believes this non-IFRS financial information, where included, provides useful information to users in measuring the financial performance and conditions of Vita. The non-IFRS financial information measures do not have standardised meanings prescribed by International Financial Reporting Standards and, therefore, may not be comparable to similarly titled measures presented by other entities, nor should they be considered as an alternative to other financial measures determined in accordance with International Financial Reporting Standards. Undue reliance should not be placed on any non-IFRS financial information.

This presentation is not and should not be considered as an offer or an invitation to acquire shares in Vita or any other financial product and does not and will not form any part of any contract for the acquisition of shares.

This presentation should be read in conjunction with other publicly available material. Further information including historical results and a description of the activities of Vita is available on our website, www.vitagroup.com.au